---
title: "InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284017056.md"
description: "InnoCare Pharma Ltd. plans to adopt a 2026 RMB Share Incentive Scheme at its upcoming annual general meeting to enhance employee alignment with shareholder interests. The scheme aims to attract key talent and motivate staff. Shareholders will vote on the scheme and its implementation. The company has received a waiver from the Hong Kong Stock Exchange, allowing RMB shares to be issued without requiring a listing in Hong Kong. The latest analyst rating for InnoCare Pharma (HK:9969) is a Buy with a price target of HK$18.31."
datetime: "2026-04-24T13:38:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284017056.md)
  - [en](https://longbridge.com/en/news/284017056.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284017056.md)
---

# InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

InnoCare Pharma Ltd. ( (HK:9969) ) has issued an update.

InnoCare Pharma plans to adopt a new 2026 RMB Share Incentive Scheme at its upcoming annual general meeting to strengthen its long-term incentive mechanisms and tie employees’ interests more closely to those of shareholders. The scheme aims to attract and retain key talent, motivate staff, and align core teams with the company’s long-term development.

Shareholders will be asked to approve the scheme, its mandate limit, related assessment measures, the issuance of new RMB shares under it, and authorization for the board to manage its implementation. The company has also secured a one-off waiver from the Hong Kong Stock Exchange so that RMB shares issued under the plan will not require listing in Hong Kong, with certain listing rule requirements modified to apply only to holders of Hong Kong-listed shares.

The most recent analyst rating on (HK:9969) stock is a Buy with a HK$18.31 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.

**More about InnoCare Pharma Ltd.**

InnoCare Pharma Limited is a biopharmaceutical company listed in Hong Kong that focuses on developing and commercializing innovative therapies. The company operates in both the Hong Kong and mainland China capital markets, issuing Hong Kong dollar and RMB-denominated shares to support its growth and incentivize its employees and core teams.

**Average Trading Volume:** 8,414,109

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$21.04B

Learn more about 9969 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [A Look At InnoCare Pharma (SEHK:9969) Valuation As Dermatology Trials For Soficitinib Progress](https://longbridge.com/en/news/276680348.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)
- [BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026](https://longbridge.com/en/news/287043048.md)
- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [US Senator Durbin urges RFK. Jr to resist easing vape rules](https://longbridge.com/en/news/287079463.md)